Grace Therapeutics, Inc. Common Stock
$2.11
Market Cap
$44.81M
Shares Outstanding
21.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 26, 2011
Round Lot
100
Locale
US
Day Open
$2.14
Day High
$2.17
Day Low
$2.10
Volume
83.7K
VWAP
$2.12
Prev Close
$2.13
Transactions
--
Acc. Volume
--
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Grace Therapeutics, Inc. Common Stock (GRCE) closed the 2026-09-18 session at $2.11, down 0.94% versus the previous close (-0.02). The stock opened at $2.14 and traded between $2.10 and $2.17 during that session. Session trading volume was 84K shares. The volume-weighted average price (VWAP) is $2.12.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Grace Therapeutics, Inc. Common Stock has a market capitalization of $44.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GRCE is listed on the XNAS exchange. The company employs approximately 5 people. Grace Therapeutics, Inc. Common Stock is headquartered in PRINCETON, NJ. The recorded listing date is 2011-04-26.
On this page you can find market GRCE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.